Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia
Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this ag...
Gespeichert in:
Veröffentlicht in: | Pediatric blood & cancer 2021-07, Vol.68 (7), p.e28940-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 7 |
container_start_page | e28940 |
container_title | Pediatric blood & cancer |
container_volume | 68 |
creator | Ibrahimova, Azada Winestone, Lena E. Miller, Tamara P. Kettler, Kyle Seif, Alix E. Huang, Yuan‐Shung Elgarten, Caitlin W. Myers, Regina M. Fisher, Brian T. Aplenc, Richard Getz, Kelly D. |
description | Background
Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group.
Methods
In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis.
Results
Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants.
Conclusions
Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL. |
doi_str_mv | 10.1002/pbc.28940 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8283996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2533602033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhoNYbK1e-AdkwBsLbpuv2UluCrr4USjYC70OJ8kZmzofa5KxbH-92Z26aKEQSDh58nBOXkJeMXrKKOVna-tOudKSPiFHrJb1oqasebo_U31Inqd0U9AlrdUzcihEQ6Vm7IjAVcSEQ4YcxqECN4W8eVeFwU9uV-nHmKHbFWHwVYHHKTqsphy6cDe_CtvVwpBTdRvy9daSsepw-ol9gBfkoIUu4cv7_Zh8__Tx2-rL4vLr54vV-8uFk1LQxbIGJa1iQJWqQUvtGgDJLLdW-VZ7qzhHDp4jtl6gQ914iQ0wSz1z3opjcj5715Pt0bsyVITOrGPoIW7MCMH8fzOEa_Nj_G0UV0LrZRG8vRfE8deEKZs-JIddBwOOUzK8_KRoasFZQd88QG_KtwxlvEIJsaScClGok5lycUwpYrtvhlGzDc6U4MwuuMK-_rf7Pfk3qQKczcBt6HDzuMlcfVjNyj-iVaVh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2533602033</pqid></control><display><type>article</type><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</creator><creatorcontrib>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</creatorcontrib><description>Background
Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group.
Methods
In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis.
Results
Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants.
Conclusions
Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.28940</identifier><identifier>PMID: 33704911</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acuity ; Acute myeloid leukemia ; Anthracycline ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Children ; Diuretics ; Hematology ; Hospitals, Pediatric ; Humans ; induction mortality ; Infant ; infant leukemia ; Infants ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Lymphatic leukemia ; Mortality ; Multiple organ dysfunction syndrome ; Myeloid leukemia ; Oncology ; Pediatrics ; Resource utilization ; Retrospective Studies</subject><ispartof>Pediatric blood & cancer, 2021-07, Vol.68 (7), p.e28940-n/a</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</citedby><cites>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</cites><orcidid>0000-0003-2020-5153</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.28940$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.28940$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33704911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ibrahimova, Azada</creatorcontrib><creatorcontrib>Winestone, Lena E.</creatorcontrib><creatorcontrib>Miller, Tamara P.</creatorcontrib><creatorcontrib>Kettler, Kyle</creatorcontrib><creatorcontrib>Seif, Alix E.</creatorcontrib><creatorcontrib>Huang, Yuan‐Shung</creatorcontrib><creatorcontrib>Elgarten, Caitlin W.</creatorcontrib><creatorcontrib>Myers, Regina M.</creatorcontrib><creatorcontrib>Fisher, Brian T.</creatorcontrib><creatorcontrib>Aplenc, Richard</creatorcontrib><creatorcontrib>Getz, Kelly D.</creatorcontrib><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Background
Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group.
Methods
In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis.
Results
Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants.
Conclusions
Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</description><subject>Acuity</subject><subject>Acute myeloid leukemia</subject><subject>Anthracycline</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Children</subject><subject>Diuretics</subject><subject>Hematology</subject><subject>Hospitals, Pediatric</subject><subject>Humans</subject><subject>induction mortality</subject><subject>Infant</subject><subject>infant leukemia</subject><subject>Infants</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Lymphatic leukemia</subject><subject>Mortality</subject><subject>Multiple organ dysfunction syndrome</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Resource utilization</subject><subject>Retrospective Studies</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1rFDEUhoNYbK1e-AdkwBsLbpuv2UluCrr4USjYC70OJ8kZmzofa5KxbH-92Z26aKEQSDh58nBOXkJeMXrKKOVna-tOudKSPiFHrJb1oqasebo_U31Inqd0U9AlrdUzcihEQ6Vm7IjAVcSEQ4YcxqECN4W8eVeFwU9uV-nHmKHbFWHwVYHHKTqsphy6cDe_CtvVwpBTdRvy9daSsepw-ol9gBfkoIUu4cv7_Zh8__Tx2-rL4vLr54vV-8uFk1LQxbIGJa1iQJWqQUvtGgDJLLdW-VZ7qzhHDp4jtl6gQ914iQ0wSz1z3opjcj5715Pt0bsyVITOrGPoIW7MCMH8fzOEa_Nj_G0UV0LrZRG8vRfE8deEKZs-JIddBwOOUzK8_KRoasFZQd88QG_KtwxlvEIJsaScClGok5lycUwpYrtvhlGzDc6U4MwuuMK-_rf7Pfk3qQKczcBt6HDzuMlcfVjNyj-iVaVh</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Ibrahimova, Azada</creator><creator>Winestone, Lena E.</creator><creator>Miller, Tamara P.</creator><creator>Kettler, Kyle</creator><creator>Seif, Alix E.</creator><creator>Huang, Yuan‐Shung</creator><creator>Elgarten, Caitlin W.</creator><creator>Myers, Regina M.</creator><creator>Fisher, Brian T.</creator><creator>Aplenc, Richard</creator><creator>Getz, Kelly D.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2020-5153</orcidid></search><sort><creationdate>202107</creationdate><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><author>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acuity</topic><topic>Acute myeloid leukemia</topic><topic>Anthracycline</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Children</topic><topic>Diuretics</topic><topic>Hematology</topic><topic>Hospitals, Pediatric</topic><topic>Humans</topic><topic>induction mortality</topic><topic>Infant</topic><topic>infant leukemia</topic><topic>Infants</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Lymphatic leukemia</topic><topic>Mortality</topic><topic>Multiple organ dysfunction syndrome</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Resource utilization</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ibrahimova, Azada</creatorcontrib><creatorcontrib>Winestone, Lena E.</creatorcontrib><creatorcontrib>Miller, Tamara P.</creatorcontrib><creatorcontrib>Kettler, Kyle</creatorcontrib><creatorcontrib>Seif, Alix E.</creatorcontrib><creatorcontrib>Huang, Yuan‐Shung</creatorcontrib><creatorcontrib>Elgarten, Caitlin W.</creatorcontrib><creatorcontrib>Myers, Regina M.</creatorcontrib><creatorcontrib>Fisher, Brian T.</creatorcontrib><creatorcontrib>Aplenc, Richard</creatorcontrib><creatorcontrib>Getz, Kelly D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ibrahimova, Azada</au><au>Winestone, Lena E.</au><au>Miller, Tamara P.</au><au>Kettler, Kyle</au><au>Seif, Alix E.</au><au>Huang, Yuan‐Shung</au><au>Elgarten, Caitlin W.</au><au>Myers, Regina M.</au><au>Fisher, Brian T.</au><au>Aplenc, Richard</au><au>Getz, Kelly D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2021-07</date><risdate>2021</risdate><volume>68</volume><issue>7</issue><spage>e28940</spage><epage>n/a</epage><pages>e28940-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Background
Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group.
Methods
In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis.
Results
Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants.
Conclusions
Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33704911</pmid><doi>10.1002/pbc.28940</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2020-5153</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1545-5009 |
ispartof | Pediatric blood & cancer, 2021-07, Vol.68 (7), p.e28940-n/a |
issn | 1545-5009 1545-5017 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8283996 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Acuity Acute myeloid leukemia Anthracycline Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child Children Diuretics Hematology Hospitals, Pediatric Humans induction mortality Infant infant leukemia Infants Leukemia Leukemia, Myeloid, Acute - drug therapy Lymphatic leukemia Mortality Multiple organ dysfunction syndrome Myeloid leukemia Oncology Pediatrics Resource utilization Retrospective Studies |
title | Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A56%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Presentation%20acuity,%20induction%20mortality,%20and%20resource%20utilization%20in%20infants%20with%20acute%20leukemia&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Ibrahimova,%20Azada&rft.date=2021-07&rft.volume=68&rft.issue=7&rft.spage=e28940&rft.epage=n/a&rft.pages=e28940-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.28940&rft_dat=%3Cproquest_pubme%3E2533602033%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2533602033&rft_id=info:pmid/33704911&rfr_iscdi=true |